Genmab A/S (NASDAQ:GMAB) Price Target Cut to $40.00 by Analysts at Guggenheim

Genmab A/S (NASDAQ:GMAB) had its price objective reduced by investment analysts at Guggenheim from $45.00 to $40.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 37.13% from the stock’s current price.

A number of other equities research analysts have also commented on the stock. HC Wainwright upped their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Finally, Jefferies Financial Group initiated coverage on Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.70.

Genmab A/S Trading Down 0.4%

Shares of GMAB traded down $0.12 during trading hours on Monday, hitting $29.17. The company had a trading volume of 1,146,283 shares, compared to its average volume of 1,834,491. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $35.43. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The stock’s 50 day moving average price is $32.15 and its 200 day moving average price is $30.03. The firm has a market cap of $18.74 billion, a P/E ratio of 18.82, a P/E/G ratio of 0.96 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. On average, research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its holdings in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after buying an additional 603 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Genmab A/S by 2.0% during the second quarter. Oppenheimer Asset Management Inc. now owns 254,551 shares of the company’s stock worth $5,259,000 after acquiring an additional 5,083 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Genmab A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 749,603 shares of the company’s stock worth $15,487,000 after purchasing an additional 13,277 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Genmab A/S by 1,591.0% during the second quarter. Hantz Financial Services Inc. now owns 5,428 shares of the company’s stock valued at $112,000 after purchasing an additional 5,107 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its holdings in shares of Genmab A/S by 293.1% during the second quarter. Campbell & CO Investment Adviser LLC now owns 107,217 shares of the company’s stock valued at $2,215,000 after purchasing an additional 79,945 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.